Form 4: Rhythm Pharmaceuticals Director Trades Common Stock

Stuart A. Arbuckle, a Director at Rhythm Pharmaceuticals, Inc., reported transactions involving the acquisition and disposition of company common stock and restricted stock units.

Summary

• Director Stuart A. Arbuckle engaged in several transactions on June 23, 2026, and June 24, 2026.
• On June 23, 2026, 4,712 shares of common stock were acquired, bringing the total beneficially owned to 11,712.
• On June 24, 2026, 3,691 stock options to buy common stock were acquired with an exercise price of $107.55.
• Also on June 24, 2026, 2,324 restricted stock units were acquired.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions related to compensation and stock ownership, rather than significant strategic shifts or performance indicators.

Positives

• Director Arbuckle acquired additional stock options and restricted stock units, indicating continued alignment with the company's performance.
• The acquisition of 4,712 shares of common stock on June 23, 2026, increases direct beneficial ownership.

Negatives

• The filing indicates a disposition of 4,712 shares of common stock on June 23, 2026, though the net effect on beneficial ownership is an increase due to other acquisitions.

Future Outlook

The filing details the vesting schedules for stock options and restricted stock units, with full vesting expected by June 24, 2027, or the day prior to the Issuer's next annual meeting of stockholders in 2027, subject to continued service.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported transactions, including stock options and RSUs, are typical compensation and incentive mechanisms within the biopharmaceutical industry.

Stakeholder Impact

• Shareholders: The transactions reflect director compensation and potential future dilution if options are exercised and RSUs are vested, but also indicate insider confidence through acquisition of equity.

Next Steps

• Vesting of stock options and restricted stock units acquired on June 24, 2026, is expected by June 24, 2027, or the day prior to the Issuer's next annual meeting of stockholders in 2027, contingent on continued service.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Rhythm Pharmaceuticals, RYTM, Director Transactions, Beneficial Ownership